AstraZeneca, Oxford aim to produce Omicron-targeted vaccine | Inquirer News

AstraZeneca, Oxford aim to produce Omicron-targeted vaccine

/ 09:02 AM December 22, 2021

FILE PHOTO: A doctor shows vials of AstraZeneca's COVID-19 vaccine in his general practice facility, as the spread of the coronavirus disease (COVID-19) continues, in Vienna, Austria May 13, 2021. REUTERS/Leonhard Foeger

FILE PHOTO: A doctor shows vials of AstraZeneca’s COVID-19 vaccine in his general practice facility, as the spread of the coronavirus disease (COVID-19) continues, in Vienna, Austria May 13, 2021. REUTERS/Leonhard Foeger

AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine.

“Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data,” a spokesperson for the company said in a statement.

Article continues after this advertisement

Oxford did not immediately respond to a request for comment outside business hours.

FEATURED STORIES

The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford.

“Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realised,” Douglas told FT.

Article continues after this advertisement

A lab-study last week found that AstraZeneca’s antibody cocktail Evusheld retained neutralising activity against the Omicron variant.

Vaccine makers Pfizer/BioNTech and Moderna also previously said they were working on Omicron- specific COVID-19 vaccines. Moderna said hopes to start clinical trials early next year.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: AstraZeneca

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.